Skip to main content
. 2014 Jun 6;9(6):e99021. doi: 10.1371/journal.pone.0099021

Figure 2. Prescription changes among cabergoline/pergolide user in one year before and after the 2007 measures.

Figure 2

Continue CP: Continued cabergoline or pergolide until the end of the study period. Switch: Switched to other anti-Parkinson drugs. Discontinue All: Discontinued all anti-Parkinson drugs at once. Continue Other: Continued other anti-Parkinson drugs that had been co-prescribed. Nine patients switched from cabergoline or pergolide to other anti-Parkinson drugs (seven to pramipexole, one to ropinirole, and one to talipexole) during the period before April 2007 (three) and after April 2007 (six). Twenty-three patients were prescribed cabergoline or pergolide before April 2007 and continued after the 2007 revision: 18 were in the Continue CP group, four were in the Switch group, and one was in the Discontinue All group.